SCHEMBL4382959

SCHEMBL4382959

Nc1nc2ccncc2c2[nH]c(O)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.36
EP300 Q09472 1/20 0.36
KAT2B Q92831 1/20 0.36
KAT8 Q9H7Z6 1/20 0.36
RPS6KA5 O75582 1/20 0.34
DYRK1A Q13627 1/20 0.33
KDM4E B2RXH2 3/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.31
RAD52 P43351 1/20 0.31
EGFR P00533 1/20 0.31
CHUK O15111 1/20 0.31
KDM4C Q9H3R0 2/20 0.30
MEN1 O00255 1/20 0.30
KDM6B O15054 1/20 0.30
KDM4A O75164 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4378158 0.74 CLK1 (0.40) CLK1RPS6KA5DYRK1AKDM4EPOLB
SCHEMBL4390007 0.71 PRMT5 (0.41) DYRK1AKDM4EHTTALDH1A1MAPT
SCHEMBL4377817 0.70 DHFR (0.40) KDM4EHTTEGFRMEN1ALDH1A1
SCHEMBL30833226 0.65 ACHE (0.41) RPS6KA5KDM4EPOLBCHUKMEN1
SCHEMBL26157498 0.64 DCPS (0.55) CLK1DYRK1AKDM4EPOLBHTT
SCHEMBL34462940 0.64 SMN1; SMN2 (0.50) RPS6KA5KDM4EALDH1A1KMT2A
SCHEMBL1302077 0.63 TLR7 (0.43) CLK1RPS6KA5DYRK1A
SCHEMBL787142 0.62 QTRT1 (0.51) KDM4EPOLBHTTRAD52MEN1
SCHEMBL3352424 0.61 KDM4C (0.45) CLK1DYRK1AKDM4CKDM4AACHE
SCHEMBL24175001 0.61 CLK1 (0.42) CLK1EP300KAT2BKAT8RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329721-B2 Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-12-11 US disclosed
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS PFIZER INC. 2009-12-03 US disclosed
WO-2007143526-A2 SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-12-13 WO disclosed
WO-2007106854-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZONAPHTHYRIDINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS IL2, IL4, IFNG CLK1 4821/4885EP300 1390/4885KAT2B 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.